Related Experiment Video
Updated: May 2, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
[Aspirin: once or twice a day?]
Pierre Fontana1, Alessandro Casini2, Françoise Boehlen3
1Service d'angiologie et d'hémostase, HUG, 1211 Genève 14. pierre.fontana@hcuge.ch
Insights
Daily aspirin dosing may be less effective for patients with increased platelet turnover, like those with diabetes. Twice-daily dosing might offer more consistent platelet inhibition in these individuals, supporting personalized antiplatelet therapy.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Hematology
Context:
- Aspirin is a standard for preventing ischemic events, typically prescribed once daily.
- This regimen is based on a daily platelet renewal rate of 10-15%.
Purpose:
- To review aspirin dosing strategies in specific patient populations.
- To address the controversy surrounding personalized antiplatelet therapy.
Summary:
- Once-daily aspirin may provide insufficient platelet inhibition when platelet turnover is elevated (e.g., in diabetes, essential thrombocytemia).
- Studies suggest increased platelet function recovery between doses with standard regimens.
- Twice-daily aspirin dosing may achieve more homogeneous platelet inhibition in these patients.
Impact:
- Challenges conventional once-daily aspirin dosing recommendations.
- Highlights the need for personalized antiplatelet strategies.
- Informs clinical practice for patients requiring enhanced ischemic event prevention.
Abstract:
Aspirin is a cornerstone in the prevention of ischemic events and guidelines usually recommend a once-daily dosing. This dosing is based at least in part on the platelet renewal rate, which is of only 10-15% a day. A once-daily dosing is now challenged by several studies demonstrating that when platelet turnover is increased, such as in patients with diabetes or essential thrombocytemia, the inhibition of platelet function provided by aspirin is no longer homogeneous between dosing with a significant recovery of platelet function within a day that is blunted by a twice-daily dosing. This review addresses the issue of aspirin dosing in selected patients in the controversial era of personalized antiplatelet therapy.
Related Concept Videos
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Dosage Regimen: Multiple Oral Dosage
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug Accumulation During Multiple Dosing: Repetitive IV Injections

